Assessment of the U.S. Food and Drug Administration's risk evaluation and mitigation strategy (REMS) for prasugrel (EFFIENT): A narrative review

Background: Prasugrel, first approved in 2009, was subject to a US Food and Drug Administration (FDA) Risk Evaluation and Mitigation Strategy (REMS) to mitigate the risk of bleeding associated with its use. Methods: We performed a narrative review of FDA documents obtained through a Freedom of Infor...

Повний опис

Бібліографічні деталі

Автори:	Thomas Metkus, Jill Curran, Shanshan Lin, Dima M. Qato, G. Caleb Alexander
Формат:	Artigo
Мова:	Inglês
Опубліковано:	Elsevier 2024-02-01
Серія:	American Heart Journal Plus
Предмети:	U.S. Food and Drug Administration Risk evaluation and mitigation programs Drug risks
Онлайн доступ:	http://www.sciencedirect.com/science/article/pii/S2666602224000028
Теги:	Додати тег Немає тегів, Будьте першим, хто поставить тег для цього запису!